Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
Want to see AU:CYP full AI Analyst Report?
CYP Stock Chart & Stats
AU$0.29
-AU$0.01(-4.17%)
At close: 4:00 PM EST
AU$0.29
-AU$0.01(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.15 - AU$0.44
Previous CloseN/A
Volume63.41K
Average Volume (3M)233.82K
Market Cap
AU$64.52M
Enterprise ValueAU$65.58M
Total Cash (Recent Filing)AU$5.05M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding243,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$17.10M
Bulls Say, Bears Say
Bulls Say
Scalable IPSC-derived MSC ManufacturingCynata's iPSC‑derived MSC platform is built for consistent, off‑the‑shelf manufacturing. Durable manufacturing consistency reduces batch variability, lowers per‑unit costs at scale, and supports commercial supply agreements and partnering if clinical programs succeed.
Clinical‑stage Programs In Immune/inflammatory DiseaseAdvancing multiple clinical‑stage programs in ARDS and GvHD provides a clear development pathway and indication diversification. Successful clinical readouts or steady progress can unlock licensing, milestone revenue and long‑term commercial opportunities across immune/inflammatory markets.
Debt‑free Balance SheetZero debt materially reduces fixed financial obligations and bankruptcy risk, improving flexibility. A debt‑free structure lengthens runway between financing events and makes partnership or non‑dilutive funding easier to negotiate, preserving optionality during clinical development.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business consumes capital to fund R&D and trials. Over the medium term this forces reliance on equity raises, licensing deals or grants, increasing dilution risk and constraining strategic choices if capital markets tighten.
No Established Product RevenueAs a pre‑commercial biotech, Cynata lacks recurring product sales and depends on financing or partnerships. Without commercialization, revenue predictability is low and the company remains exposed to trial outcomes, making sustainable investment in scale and operations contingent on future approvals or deals.
Large Operating Losses; Declining EquitySustained large losses and material declines in equity/assets erode shareholder capital and reflect negative returns on invested funds. Over months this weakens financial flexibility, raises governance scrutiny, and necessitates more frequent financing or asset sales to sustain clinical programs.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.43 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$64.52M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 82 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 243,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-179.37%
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―